Treatment of type 2 diabetes mellitus.
Although most patients with type 2 diabetes mellitus can be initially managed with diet and exercise alone, most eventually require at least oral agents if not insulin to maintain glycemic control. Appropriate therapeutic regimens may be difficult to design, given the diversity of drugs available for clinical use. Physicians must consider not only glycemic control, but also patient preference, concomitant medical conditions, and cost when designing therapeutic regimens.
Feinglos
M N
MN
Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
Bethel
M A
MA
D001645:Biguanides / Q000009:adverse effects / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism; D002839:Chromans / Q000009:adverse effects / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000178:diet therapy / Q000188:drug therapy / Q000191:economics / Q000628:therapy*; D003927:Diet, Diabetic / Q000009:adverse effects / Q000145:classification; D005081:Exercise Therapy / Q000009:adverse effects / Q000379:methods; D065089:Glycoside Hydrolase Inhibitors; D017048:Health Care Costs; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007328:Insulin / Q000009:adverse effects / Q000627:therapeutic use; D010349:Patient Compliance; D010358:Patient Participation; D013453:Sulfonylurea Compounds / Q000009:adverse effects / Q000627:therapeutic use; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use; D045162:Thiazolidinediones; D000077288:Troglitazone
D001645:Biguanides; D001786:Blood Glucose; D002839:Chromans; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D007328:Insulin; D013453:Sulfonylurea Compounds; D013844:Thiazoles; D045162:Thiazolidinediones; D000077288:Troglitazone